Dr. Seropian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Bldg
New Haven, CT 06519Phone+1 203-785-4191Fax+1 203-737-2617
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997- Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1994
George Washington University School of Medicine and Health SciencesClass of 1991
Certifications & Licensure
CT State Medical License 1997 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
- Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation Start of enrollment: 2007 Oct 01
- Rapamycin for Prevention of Chronic Graft-Versus-Host Disease Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.Rachael Straining, Francine Foss, Molly Schiffer, Kejal Amin, Sonal Agarwal
Clinical Lymphoma, Myeloma & Leukemia. 2025-02-01 - Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies.Christian J Puzo, Stuart Seropian, Henry Rinder, Christopher A Tormey, Alexa J Siddon
Bone Marrow Transplantation. 2025-01-13 - 1 citationsRandomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10
Abstracts/Posters
- Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell TransplantationStuart Seropian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceStuart Seropian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
What Does It Mean to Be ‘Immunocompromised’?October 18th, 2021- Life Expectancy Still Lower for Blood or Marrow Transplant RecipientsSeptember 9th, 2021
- Yale Cancer Center Earns International Reaccreditation for Expertise in CAR T-cell Therapy and Stem Cell TransplantationMay 9th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
